Raynaud's phenomenon;Il fenomeno di Raynaud

Reumatismo

Volumn 56, Issue 2, 2004, Pages 77-81

  Zeni, Silvana ^a,b   Ingegnoli, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

Connective tissue diseases; Raynaud's phenomenon; Scleroderma

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTINUCLEAR ANTIBODY; CALCIUM CHANNEL BLOCKING AGENT; FLUOXETINE; ILOPROST; LOSARTAN; NIFEDIPINE; PRAZOSIN; PROSTAGLANDIN; SEROTONIN UPTAKE INHIBITOR;

ACROCYANOSIS; ANAMNESIS; CLIMATE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CYANOSIS; DIFFERENTIAL DIAGNOSIS; EMOTIONAL STRESS; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; HYPEREMIA; OCCUPATION; ONSET AGE; PHYSICAL EXAMINATION; PREVALENCE; RAYNAUD PHENOMENON; REVIEW; SEX RATIO; SMOKING; SYSTEMIC SCLEROSIS; VASOSPASM;

ADOLESCENT; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGE FACTORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CHILD; CONNECTIVE TISSUE DISEASES; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUOXETINE; HUMANS; LOSARTAN; MALE; NIFEDIPINE; PRAZOSIN; PROSTAGLANDINS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS;

EID: 3142691841     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Wigley FM. Raynaud's phenomenon. N Engl J Med 2002; 347: 1001-8.
2. Maricq HR, Weinrich MC. Diagnosis of Raynaud's phenomenon assisted by color charts. J Rheumatol 1988; 15: 454-9.
3. Olsen N, Nielsen SL. Prevalence of primary Raynaud's phenomenon in young females. Scand J C Lab Invest 1978; 38: 761-4.
4. Weinrich MC, Maricq HR, Keil JE, McGregor AR, Diat F. Prevalence of primary Raynaud's phenomenon the adult population of South Carolina. J Clin Epidemiol 1990; 43: 1343-9.
5. Fraenkel L, Zhang Y, Chaisson CE, Maricq HR, Evans SR, Brand F, et al. Different factors influencing the expression of Raynaud's phenomenon in men and women. Arthritis Rheum 1999; 42: 306-10.
6. Keil JE, Maricq HR, Weinrich MC, McGregor AR, Diat F. Demographic, social and clinical correlates of Raynaud phenomenon. Int J Epidemiol 1991; 20: 221-4.
7. Riera G, Vilardell M, Vaque J, Fonollosa V, Bermejo B. Prevalence of Raynaud's phenomenon in healthy Spanish population. J Rheumatol 1993; 20: 66-9.
8. Jones GT, Herrick AL, Woodham SE, Baildam EM, Macfarlane GJ, Silman A. Occurrence of Raynaud's Phenomenon in Children Ages 12-15 Years. Arthritis Rheum 2003; 48: 3518-21.
9. Planchon B, Pistorius MA, Beurrier P, Faucal P. Primary Raynaud's phenomenon: age of onset and pathogenesis in a prospective study of 424 patients. Angiology 1994; 45: 677-86.
10. Raynaud's treatment Study Investigators. Comparison of sustained release nifedipine and temperature biofeedback for treatment of primary Raynaud's phenomenon: results of a randomised clinical trial with 1 year follow-up. Arch Intern Med 2000; 160: 1101-8.
11. Freedman RR, Mayers MD. Familial aggregation of primary Raynaud's disease. Arthritis Rheum 1996; 39: 1189-91.
12. Kallemberg CG. Early detection of connective tissue disease in patients with Raynaud's phenomenon. Rheum Dis Clin North Am 1990; 16: 11-30.
13. st ed, Baltimora, Williams & Wilkins 1996; 153-74.
14. Johnson S, Iazzetta J, Dewar C. Severe Raynaud's phenomenon with yoimbine therapy for erectile dysfunction. J Rheumatol 2003; 30: 2503-5.
15. LeRoy EC, Medsger TA. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992; 10: 485-8.
16. Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary disease. Arch Intern Med 1998; 158: 595-600.
17. Kallemberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six years follow up with emphasis on the predictive value of autoantibodies as detected by immunoblotting. Ann Rheum Dis 1988; 47: 634-4.
18. Faravelli C, Zeni S, Cirla E, Fantini F. Gli autoanticorpi anticentromero e anti-Scl 70 nell'inquadramento diagnostico della sclerodermia. Reumatismo 1990; 2: 115-24.
19. Wollersheim H, Thien T, Hoet MH, van Venrooij WJ. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. Eur J Clin Invest 1989; 19: 535-41.
20. Harper FE, Maricq HR, Turner RE, Lindman RW, LeRoy EC. A prospective study of Raynaud phenomenon and early connective tissue disease: a five-year report. Am J Med 1982; 72: 883-8.
21. Zuffery P, Depairon M, Chamot AM, Monti M. Prognostic significance of nailfold capillary microscopy in patients with Raynaud's phenomenon and scleroderma pattern abnormalities: a six-years follow up study. Clin Rheumatol 1992; 11: 536-41.
22. Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer-Green G. The evolution of Raynaud's phenomenon: a long term prospective study. J Rheumatol 1995; 22: 2226-32.
23. Cutolo M, Grassi W, Matucci Cerinic M. Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 2003; 48: 3023-30.
24. Coffman JD, Rasmussen HM. Effects of β-adrenoreceptor-blocking drugs in patients with Raynaud's phenomenon. Circulation 1985; 72: 466-70.
25. Goodfield MJ, Hume A, Rowell NR. The acute effects of cigarette smoking on cutaneous blood flow in smoking and non smoking subjects with and without Raynaud's phenomenon. Br J Rheumatol 1990; 29: 89-91.
26. Palesch YY, Valter I, Carpentier PH, Maricq HR. Association between cigarette and alcohol consumption and Raynaud's phenomenon. J Clin Epidemiol 199; 52: 321-8.
27. Pope J, Fenlon D, Thompson A. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000; 2: CD000956.
28. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomised, parallel group, controlled trial. Arthritis Rheum 1999; 42: 2646-55.
29. Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsch, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001; 40: 1038-1043.
30. Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomised, controlled study. Clin Exp Rheumatol 2001; 19: 503-8.
31. Zeni S, Soldi A, Cossutta R, Colombelli P, Fantini F. Effetti del trattamento periodico con iloprost EV sull'evoluzione della sclerosi sistemica. Studio longitudinale di 1 anno. Reumatismo 2000; 52 (Suppl 2): 164.
32. Arreghini M, Prudente P, Maglione W, Arnoldi C, Tosi S, Marchesoni A. Tollerabilità, sicurezza ed efficacia del trattamento infusivo con iloprost senza pompa peristaltica in pazienti affetti da sclerosi sistemica. Reumatismo 2001; 53: 140-44.
33. Bettoni L, Geri A, Airò P, Danieli E, Cavazzana I, Antonioli C, et al. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 2002; 21: 244-50.